anpirtoline has been researched along with Brain Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barann, M; Bönisch, H; Göthert, M; Gozlan, H; Hamon, M; Laguzzi, R; Metzenauer, P; Nickel, B; Szelenyi, I | 1 |
1 other study(ies) available for anpirtoline and Brain Neoplasms
| Article | Year |
|---|---|
5-HT3 receptor antagonism by anpirtoline, a mixed 5-HT1 receptor agonist/5-HT3 receptor antagonist.
Topics: Animals; Antidepressive Agents; Antiemetics; Brain Neoplasms; Cisplatin; Entorhinal Cortex; In Vitro Techniques; Male; Mice; Neuroblastoma; Piperidines; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Reflex; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Swine; Tumor Cells, Cultured | 1995 |